ponatinib,Blinatumomab
otsuka,takeda,incyte,astellas,amgen
['leusm', 'ponatinib']
#ash22 #leusm short: 96% cr/cri with ponatinib+blin. 87% cmr (88% ngs neg, small number with persistent bcr-abl+ while ngs neg), 68% mrd neg after one cycle. two relapses of n=40; 35 in ongoing cr without allohct. 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)